Organogenesis Historical Balance Sheet
ORGO Stock | USD 3.87 0.03 0.77% |
Trend analysis of Organogenesis Holdings balance sheet accounts such as Total Stockholder Equity of 179.4 M provides information on Organogenesis Holdings' total assets, liabilities, and equity, which is the actual value of Organogenesis Holdings to its prevalent stockholders. By breaking down trends over time using Organogenesis Holdings balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Organogenesis Holdings latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Organogenesis Holdings is a good buy for the upcoming year.
Organogenesis Holdings Inventory |
|
Organogenesis |
About Organogenesis Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Organogenesis Holdings at a specified time, usually calculated after every quarter, six months, or one year. Organogenesis Holdings Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Organogenesis Holdings and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Organogenesis currently owns. An asset can also be divided into two categories, current and non-current.
Organogenesis Holdings Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Organogenesis Holdings assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Organogenesis Holdings books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Organogenesis Holdings balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Organogenesis Holdings are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most accounts from Organogenesis Holdings' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Organogenesis Holdings current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organogenesis Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.At this time, Organogenesis Holdings' Property Plant Equipment is very stable compared to the past year. As of the 2nd of December 2024, Net Debt is likely to grow to about 16.3 M, while Total Assets are likely to drop about 292.5 M.
2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 25.6M | 23.8M | 13.1M | 11.5M | Total Assets | 443.3M | 449.4M | 460.0M | 292.5M |
Organogenesis Holdings balance sheet Correlations
Click cells to compare fundamentals
Organogenesis Holdings Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Organogenesis Holdings balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 220.7M | 294.5M | 443.3M | 449.4M | 460.0M | 292.5M | |
Other Current Liab | 5.8M | 24.6M | 25.6M | 23.8M | 13.1M | 11.5M | |
Total Current Liabilities | 59.9M | 68.2M | 82.0M | 75.0M | 80.5M | 48.2M | |
Total Stockholder Equity | 55.6M | 146.1M | 242.0M | 265.7M | 278.7M | 179.4M | |
Other Liab | 7.7M | 15.7M | 1.6M | 1.1M | 1.3M | 1.2M | |
Net Tangible Assets | 9.2M | 86.7M | 187.6M | 216.1M | 248.5M | 261.0M | |
Retained Earnings | (171.0M) | (153.1M) | (60.1M) | (45.3M) | (41.0M) | (43.0M) | |
Accounts Payable | 28.4M | 23.4M | 29.3M | 32.3M | 30.7M | 23.8M | |
Cash | 60.2M | 84.4M | 113.9M | 102.5M | 104.3M | 53.7M | |
Other Assets | 1.6M | 688K | 33.5M | 31.5M | 1.0 | 0.95 | |
Long Term Debt | 83.1M | 53.0M | 70.8M | 66.2M | 60.7M | 65.7M | |
Net Receivables | 39.4M | 56.8M | 82.5M | 89.5M | 82.0M | 52.7M | |
Common Stock Total Equity | 293.0M | 9K | 10K | 13K | 11.7K | 11.1K | |
Inventory | 22.9M | 27.8M | 25.0M | 24.8M | 28.3M | 20.8M | |
Other Current Assets | 3.0M | 5.3M | 5.6M | 5.9M | 10.5M | 11.0M | |
Other Stockholder Equity | 226.6M | 296.8M | 302.9M | 311.0M | 319.6M | 181.1M | |
Total Liab | 165.1M | 148.4M | 201.2M | 183.7M | 181.4M | 113.0M | |
Deferred Long Term Liab | 318K | 92K | 370K | 1.2M | 1.4M | 1.5M | |
Total Current Assets | 125.6M | 174.3M | 227.0M | 222.6M | 225.0M | 115.3M | |
Short Term Debt | 3.1M | 20.3M | 26.6M | 16.2M | 33.9M | 35.6M | |
Intangible Assets | 20.8M | 30.6M | 25.7M | 20.8M | 15.9M | 22.1M | |
Common Stock | 293.0M | 9K | 10K | 13K | 11.7K | 11.1K | |
Property Plant Equipment | 47.2M | 60.1M | 79.2M | 102.5M | 117.8M | 123.7M | |
Short Long Term Debt Total | 100.6M | 84.8M | 132.3M | 123.8M | 119.4M | 85.3M | |
Net Debt | 40.4M | 377K | 18.4M | 21.3M | 15.5M | 16.3M | |
Non Current Assets Total | 95.1M | 120.2M | 216.3M | 226.8M | 235.0M | 196.6M | |
Non Currrent Assets Other | 884K | 670K | 1.5M | 1.5M | 6.0M | 5.7M | |
Cash And Short Term Investments | 60.2M | 84.4M | 113.9M | 102.5M | 104.3M | 59.6M | |
Common Stock Shares Outstanding | 92.8M | 111.4M | 133.7M | 132.4M | 132.7M | 105.4M | |
Liabilities And Stockholders Equity | 220.7M | 294.5M | 443.3M | 449.4M | 460.0M | 324.6M | |
Non Current Liabilities Total | 105.2M | 80.2M | 119.2M | 108.7M | 100.9M | 71.7M | |
Capital Surpluse | 226.6M | 299.1M | 302.2M | 311.0M | 357.6M | 182.7M | |
Non Current Liabilities Other | 6.6M | 12.0M | 48.5M | 42.4M | 1.2M | 1.2M | |
Net Invested Capital | 138.7M | 215.8M | 315.5M | 336.4M | 344.9M | 273.1M | |
Net Working Capital | 65.7M | 106.1M | 145.0M | 147.6M | 144.5M | 95.9M | |
Property Plant And Equipment Net | 47.2M | 60.1M | 128.3M | 145.7M | 156.3M | 105.8M |
Pair Trading with Organogenesis Holdings
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Organogenesis Holdings position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Organogenesis Holdings will appreciate offsetting losses from the drop in the long position's value.Moving against Organogenesis Stock
0.85 | VALN | Valneva SE ADR | PairCorr |
0.85 | DRRX | Durect | PairCorr |
0.8 | ME | 23Andme Holding Upward Rally | PairCorr |
0.71 | DNTH | Dianthus Therapeutics | PairCorr |
0.63 | DOMH | Dominari Holdings | PairCorr |
The ability to find closely correlated positions to Organogenesis Holdings could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Organogenesis Holdings when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Organogenesis Holdings - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Organogenesis Holdings to buy it.
The correlation of Organogenesis Holdings is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Organogenesis Holdings moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Organogenesis Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Organogenesis Holdings can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organogenesis Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organogenesis Holdings. If investors know Organogenesis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organogenesis Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 3.5 | Earnings Share (0.05) | Revenue Per Share 3.446 | Quarterly Revenue Growth 0.061 | Return On Assets 0.0164 |
The market value of Organogenesis Holdings is measured differently than its book value, which is the value of Organogenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Organogenesis Holdings' value that differs from its market value or its book value, called intrinsic value, which is Organogenesis Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organogenesis Holdings' market value can be influenced by many factors that don't directly affect Organogenesis Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Organogenesis Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Organogenesis Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organogenesis Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.